- Home
- Publications
- Publication Search
- Publication Details
Title
Long-acting antiretrovirals and HIV treatment adherence
Authors
Keywords
-
Journal
Lancet HIV
Volume 10, Issue 5, Pages e332-e342
Publisher
Elsevier BV
Online
2023-04-14
DOI
10.1016/s2352-3018(23)00051-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study
- (2022) Nicolas Margot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effects of behavioural interventions on postpartum retention and adherence among women with HIV on lifelong ART: the results of a cluster randomized trial in Kenya (the MOTIVATE trial)
- (2022) Lisa L. Abuogi et al. Journal of the International AIDS Society
- Long-acting injectable ART for HIV: a (cautious) step forward
- (2022) Priya Venkatesan Lancet Microbe
- Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects
- (2022) Kelong Han et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic
- (2022) Katerina A Christopoulos et al. CLINICAL INFECTIOUS DISEASES
- Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV ‐1 in need of parenteral antiretroviral therapy
- (2022) Ronald D'Amico et al. HIV MEDICINE
- Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
- (2022) Nicolas A Margot et al. JOURNAL OF INFECTIOUS DISEASES
- Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
- (2022) Lauren F Collins et al. Open Forum Infectious Diseases
- 1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
- (2022) Michael G Sension et al. Open Forum Infectious Diseases
- 1584. CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm
- (2022) Stephane De Wit et al. Open Forum Infectious Diseases
- Early post-partum viremia predicts long-term non-suppression of viral load in HIV-positive women on ART in Malawi: Implications for the elimination of infant transmission
- (2021) Megan Landes et al. PLoS One
- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083
- (2021) Mark A Marzinke et al. JOURNAL OF INFECTIOUS DISEASES
- The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
- (2021) Andrew N Phillips et al. Lancet Global Health
- Long-acting cabotegravir + rilpivirine for HIV-1 treatment
- (2021) Susan Swindells et al. AIDS
- Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
- (2021) Paul Thoueille et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
- (2021) M Neyens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
- (2021) Raphael J. Landovitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- SMS messaging to improve retention and viral suppression in prevention of mother-to-child HIV transmission (PMTCT) programs in Kenya: A 3-arm randomized clinical trial
- (2021) John Kinuthia et al. PLOS MEDICINE
- Impact of long-acting therapies on the global HIV epidemic
- (2021) Nomathemba C. Chandiwana et al. AIDS
- A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
- (2021) Sara H. Bares et al. Current Opinion in HIV and AIDS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2021) Hans Jaeger et al. Lancet HIV
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries
- (2021) Win Min Han et al. Lancet HIV
- 885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials
- (2021) Parul Patel et al. Open Forum Infectious Diseases
- Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence
- (2021) Lisa L. Abuogi et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
- (2021) Susan H Eshleman et al. JOURNAL OF INFECTIOUS DISEASES
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placental Transfer of the integrase strand inhibitors cabotegravir and bictegravir in the Ex-Vivo Human Cotyledon Perfusion Model
- (2020) Lucile Pencolé et al. AIDS
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12‐month cohort study in urban South Africa and rural Uganda
- (2020) Lynn T Matthews et al. Journal of the International AIDS Society
- Adherence to HIV treatment regimens: systematic literature review and meta-analysis
- (2019) Frederick Altice et al. Patient Preference and Adherence
- Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities
- (2019) Sharon Nachman et al. Lancet HIV
- Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya
- (2019) Thomas A. Odeny et al. PLOS MEDICINE
- 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
- (2019) Paula Teichner et al. Open Forum Infectious Diseases
- Medication adherence in pregnant women with human immunodeficiency virus receiving antiretroviral therapy in sub-Saharan Africa: a systematic review
- (2018) Olumuyiwa Omonaiye et al. BMC PUBLIC HEALTH
- Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum
- (2018) Ahizechukwu C. Eke et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
- (2018) Deanna Kerrigan et al. PLoS One
- Interest of Youth Living with HIV in Long-Acting Antiretrovirals
- (2018) Ethel D. Weld et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Interventions to significantly improve service uptake and retention of HIV-positive pregnant women and HIV-exposed infants along the prevention of mother-to-child transmission continuum of care: systematic review
- (2017) Alexandra C. Vrazo et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
- (2016) Anna H. Tran et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
- (2016) Katharine J. Bar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics of drugs in pregnancy
- (2015) Maisa Feghali et al. SEMINARS IN PERINATOLOGY
- Physiologic and pharmacokinetic changes in pregnancy
- (2014) Maged M. Costantine Frontiers in Pharmacology
- Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries
- (2012) Jean B. Nachega et al. AIDS
- Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes
- (2010) Hyunyoung Jeong Expert Opinion on Drug Metabolism & Toxicology
- Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa
- (2009) Jean B Nachega et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now